Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

MAGE-A4 inhibitor

DRUG CLASS:

MAGE-A4 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

MAGEA4 expression	Synovial Sarcoma	MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1
HLA-A*02 + MAGEA4 expression	Solid Tumor	HLA-A*02 + MAGEA4 expression	Solid Tumor	ADP-A2M4CD8 Sensitive: C3 – Early Trials ADP-A2M4CD8 Sensitive : C3	ADP-A2M4CD8 Sensitive: C3 – Early Trials ADP-A2M4CD8 Sensitive : C3
HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3
HLA-A*02 + MAGEA4 expression	Ovarian Cancer	HLA-A*02 + MAGEA4 expression	Ovarian Cancer	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3
HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3